Heat Biologics’ core team has all been personally touched by cancer or has witnessed firsthand the devastating effects of cancer or its current treatment methods on loved ones.
We are fully dedicated to helping to eradicate cancer through the development of safer, more effective therapies that enhance the immune system instead of destroying it.
Founder and CEO
Jeffrey Wolf is the founder and CEO of Heat Biologics. He was formerly the founder and managing director at Seed-One Ventures, a firm focused on the systematic formation and management of new biomedical companies based upon novel research breakthroughs.
Throughout his career Mr. Wolf has created life science startup companies and actively supported the growth of these companies. Mr. Wolf’s start-ups include Avigen (co-founder and director), a NASDAQ-listed gene therapy company; TyRx Pharma (co-founder and Chairman) which was focused on the development of novel bio-compatible polymers and recently sold to Medtronic; EluSys Therapeutics (founder and CEO), focused on the development of novel antibodies against infectious diseases and GenerationOne (founder and CEO), focused on mobile-based healthcare solutions.
Mr. Wolf received his M.B.A. from Stanford Business School, his J.D. from New York University School of Law and his B.A. from the University of Chicago, where he graduated with honors in Economics.
Jeff Hutchins, Ph.D.
Chief Scientific Officer and Senior Vice President of Preclinical Development
Dr. Hutchins oversees Heat's research efforts, bringing over 24 years of research and clinical development experience from both large pharmaceutical and biotechnology companies. Most recently, Dr. Hutchins served as Vice President of Preclinical Research for Peregrine Pharmaceuticals, Inc., a biopharmaceutical company developing therapeutics to fight cancer and infectious diseases. Dr. Hutchins was responsible for building out the research program for Peregrine's lead product candidate, bavituximab, a chimeric monoclonal antibody designed to target phosphatidylserine. Prior to joining Peregrine in 2012, Dr. Hutchins served as Vice President, Preclinical Development at Inhibitex Inc, which was acquired by Bristol-Myers Squibb From 1991 to 2000, Dr. Hutchins held several senior scientist positions in Discovery Research at Burroughs Wellcome and Glaxo Wellcome, with a visiting professor appointment at Rush Medical College. Dr. Hutchins earned a B.S. in Biology from Oral Roberts University, a Ph.D. in Biomedical Sciences from the University of Texas, Health Science Center at the M.D. Anderson Cancer Center and conducted postdoctoral training in the University of Southern California's Department of Microbiology at the Norris Cancer Center. Dr. Hutchins' publications and patents span the fields of oncology, infectious disease, osteoarthritis and immunology.
George Peoples, M.D., FACS
Chief Medical Officer
U.S. Army, COL (ret) George E. Peoples, M.D., FACS serves as Heat’s Chief Medical Officer. Dr. Peoples recently retired from 30 years of active duty as a surgeon and research scientist in the military. He is the Founder and Director of Cancer Insight, LLC, a clinical research and development organization dedicated to the discovering, developing and testing for emerging biotechnologies specializing in cancer immunotherapy. Dr. Peoples is a Professor of Surgery at Uniformed Services University of the Health Sciences and a Professor (adjunct) of Surgical Oncology at MD Anderson Cancer Center (MDACC). He is the past Chair of the Cancer Program, San Antonio Military Medical Center and the past Deputy Director of the United States Military Cancer Institute. Dr. Peoples served as the Chief of Surgical Oncology at Walter Reed Amy Medical Center (WRAMC) from 1998 to 2006 and at SAMMC from 2006 to 2014. He is a graduate of the United States Military Academy, West Point and the Johns Hopkins School of Medicine. He completed his surgical training at Harvard’s Brigham and Women’s Hospital, and during that time, also completed a postdoctoral fellowship at the Laboratory of Biologic Cancer Therapy at Harvard Medical School. He then completed a surgical oncology fellowship at MDACC before becoming Chief of Surgical Oncology at WRAMC. He has written extensively on the immune response to cancer with over 300 peer-reviewed manuscripts, abstracts and book chapters.
Ann Rosar, M.B.A.
Vice President of Finance and Corporate Secretary
Ms. Rosar has over twenty years of experience in finance with publicly held companies and more than fifteen years of experience regarding regulatory reporting requirements. Prior to serving as the Heat’s Controller, Ms. Rosar served as Manager of Financial Reporting and Accounting for LipoScience, Inc. (acquired by LabCorp), a provider of specialized cardiovascular diagnostic tests, from 2013 to 2015. From 2007 until 2013 she served in various roles at DARA Biosciences, Inc. (now Midatech Pharma US), an oncology supportive care pharmaceutical company, including the Vice President of Finance, Chief Accounting Officer and Controller. Ms. Rosar was the Manager of Financial Reporting and Accounting with Cicero, Inc. (formerly Level 8 Systems), a provider of business integration software, from June 2000 until November 2007, where she was responsible for Securities and Exchange Commission reporting, audits and budget analysis. Prior to that position, she served as Senior Financial Analyst-Business Operations for Nextel Communications.
Ms. Rosar received a M.B.A. in Finance from the University of Houston and received her undergraduate degree from North Carolina State University.